Trial Profile

A Phase Ib clinical trial for treatment of Idiopathic Pulmonary Fibrosis (IPF)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 17 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Mar 2025 According to Remedy Cell media release, Remedy Cell and Qureight collaborated to validate RC-0315's mechanism of action in idiopathic pulmonary fibrosis (IPF).
19 Mar 2024 New trial record
15 Mar 2024 According to a Pluri Inc media release, PluriCDMO has signed a manufacturing agreement with Remedy Cell Ltd and will support Remedy Cell's production team to initiate a phase Ib clinical trial RC-0315 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in early 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com